BERKELEY, Calif. — January 16, 2026 — Leads & Copy — Profusa, Inc. (Nasdaq: PFSA) has launched its Healthcare Research version of the Lumee tissue oxygen monitoring system into the contract research organizations (CRO) market, a move expected to generate immediate service-based revenue.
This initiative targets a high-growth segment of the pharmaceutical services industry, driven by increasing R&D investment and regulatory momentum around new approach methodologies (NAMs). The demand for more predictive, real-time biological data to improve drug development efficiency and decision-making is also a factor.
Profusa’s Lumee tissue oxygen products are commercially ready and available for immediate deployment, allowing CRO partners to rapidly incorporate the technology into existing study designs and offer differentiated services to their clients with minimal implementation risk.
Industry forecasts estimate the global pharmaceutical CRO market could expand from approximately $47.9 billion in 2025 to over $91.2 billion by 2034 at a CAGR of more than 7%, underscoring the expanding addressable opportunity for advanced biosensing platforms.
Building on Profusa’s established success with its Lumee oxygen tissue-integrated biosensor technologies, the company will now offer the Lumee tissue oxygen system as commercial research-use-only (RUO) kits and a service-enabled platform for CRO partners. This provides researchers and R&D teams access to continuous, real-time measurement of tissue oxygenation, providing critical insights across a range of applications including advanced in vitro and organ-on-chip models, preclinical pharmacology and toxicology studies, and translational research programs.
The Lumee tissue oxygen system supports research into complex biological processes such as tissue oxygenation dynamics in wound healing and tumor microenvironments in oncology — areas where oxygen plays a central role in therapeutic response and biological interpretation. By integrating Lumee tissue oxygen into CRO workflows, Profusa enables pharmaceutical customers to access biologically relevant data that extends well beyond traditional endpoint assays.
To help meet the demand from this industry expansion, Profusa has appointed Sean Givens to lead the commercialization efforts as the Head of Government and Healthcare Research Business.
According to Mr. Givens, Profusa’s sensors are validated, ready to ship and already generating strong interest across the industry. He believes partnering with CROs can help accelerate better drug development decisions while creating a meaningful, near-term revenue stream for Profusa.
Mr. Givens brings over 20 years of government accounting and contracting experience, as well as extensive operations experience in consumer electronics, medical devices and drug development. Most recently, Mr. Givens served as Profusa’s Head, Government Business. Prior, he was co-founder and COO of MIODx, a company focused on immune repertoire profiling to predict patient response to immunotherapy regimens.
Profusa is a commercial stage digital health company led by visionary scientific founders, an experienced management team and a world-class board of directors focused on developing a new generation of tissue-integrated sensors to detect and continuously transmit actionable, medical-grade data for personal and medical use.
With its long-lasting, injectable and affordable biosensors and its intelligent data platform, Profusa aims to provide people with a personalized biochemical signature rooted in data that clinicians can trust and rely on.
Sean Givens can be contacted via ruo.sales@profusa.com for additional information about this offering.
Source: Profusa
